Quotient sets sights on $75m IPO
This article was originally published in Clinica
Scottish firm Quotient, which specializes in blood transfusion diagnostics, is hoping to raise up to $75m in an initial public offering. The Midlothian company plans to list on the Nasdaq under the ticker symbol QTNT; it didn’t give details of how many shares it plans to sell or at what price. Founded in 2007, Quotient booked sales of $14.4m and made a net loss of $4.7m during the fiscal year ended 31 March 2013.